Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-190-8 | CAS number: 7789-79-9
Repeated oral administration through diet of Phoslite IP-A to Wistar Hannover rats at doses of 0, 100, 300 and 1000 ppm for 28 days produced no mortality and no clinical signs of toxicological relevance. Statistically significant increase on mean corpuscular hemoglobin concentration and platelet count were observed on group 4 (1,000 ppm) of females, during treatment period. Statistically significant decrease on hematocrit (HCT) was observed on group 4 (1,000 ppm).
Creatinine (CRE) concentration of females on group 4 (1,000 ppm) was statistically significant increased when compared to the control group.
Based on these results, the no-observed-adverse-effect-level (NOAEL) of Phoslite IP-A resulted to be higher than 300 ppm test item in diet for females (35.2 mg/kg body weight/day) and greater than 1000 ppm for males (86.9 mg/kg body weight/day).
The test item was administered to Wistar rats (5 animals/sex/group) in the diet for 4 weeks at doses of 0, 100, 300, 1000 ppm, equal to compound intake of 0, 9.9, 27.8 and 86.9 mg/kg/bw on males and 0, 11.4, 35.2 and 121.2 mg/kg/bw on females. Additional satellite groups (5 animals/sex/group) of the control and highest dose were maintained for more 2 weeks after the end of the treatment period for observation of reversibility or persistence of toxic effects. Body weight and food consumption were determined weekly. Animals were checked daily for mortality and morbidity (except on Sundays) and were subjected to a careful clinical examination once a week. At the end of the treatment or after recovery period, blood samples were collected for clinical chemistry, hematological and clotting analyses. During the necropsy, the animals were subjected to a gross examination and the appropriate organs and tissues were removed, weighed and submitted for histopathological examination. In general, no substance related findings were observed. In the female group treated at the highest dose, increased on PLT and MHCH and decrease on HCT were recorded after treatment. The effects were fully reversible after the recovery period.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again